Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Common Equity: 2023-2024

Historic Common Equity for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $312.5 million.

  • Zenas BioPharma's Common Equity fell 45.35% to $196.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.4 million, marking a year-over-year decrease of 45.35%. This contributed to the annual value of $312.5 million for FY2024, which is 238.43% up from last year.
  • As of FY2024, Zenas BioPharma's Common Equity stood at $312.5 million, which was up 238.43% from -$225.7 million recorded in FY2023.
  • Zenas BioPharma's Common Equity's 5-year high stood at $312.5 million during FY2024, with a 5-year trough of -$225.7 million in FY2023.
  • Over the past 2 years, Zenas BioPharma's median Common Equity value was $43.4 million (recorded in 2023), while the average stood at $43.4 million.
  • Data for Zenas BioPharma's Common Equity shows a peak YoY soared of 238.43% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Zenas BioPharma's Common Equity stood at -$225.7 million in 2023, then spiked by 238.43% to $312.5 million in 2024.